A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions

COVID-19

Interventions

DRUG

101-PGC-005 ('005) + SOC

Three consecutive days of '005 administration

DRUG

Placebo + SOC

Three consecutive days of placebo administration

Trial Locations (1)

The COVID-19 Unit, Rambam Health Care Campus, Haifa